Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Urothelial Cancer of the Bladder

NCT06809140 is registered in ClinicalTrials.gov with Matthew Galsky as lead sponsor.

NCT NCT06809140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06809140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Urothelial Cancer of the Bladder
Lead sponsor
Matthew Galsky
Phase
Phase 2
Overall status
Recruiting
Start date
April 7, 2025
Completion date
November 30, 2029
Enrollment
75 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder urothelial carcinoma